Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)

By In The News
November 26, 2019 in The Headlines

Recommended Posts

In The News

Posted November 26, 2019

- Share

Posted November 26, 2019

TOKYO, Nov. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the China National Medical Products Administration (NMPA) approved a new drug application (NDA) for XTANDI® (enzalutamide) on November 18 for...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222585
2. Jaydee
  18120
3. deicer
  13646
4. Kip Powick
  12351
5. dagger
  9615
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  273k
- Total Posts
  
  566.6k

Sign In

Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support